m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05626
 [1]
m6A modification MIR503 MIR503 METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA miR-503 PPARGC1B  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target miR-503
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator MiR-503 microRNA View Details
Regulated Target PPARG coactivator 1 beta (PPARGC1B) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary Hypoxia induced rapid H3K4 methylation of the promoter of the methyltransferase-like 3 gene (METTL3) and resulted in its overexpression. METTL3 overexpression evokes N6-methyladenosine (m6A)-dependent miR-503 biogenesis in endothelial cells. miR-503 promoted cardiomyocyte death by directly binding to PPARG coactivator 1 beta (PPARGC1B) and SIRT3, thereby triggering mitochondrial metabolic dysfunction and cardiomyocyte death. In summary, this study highlights a novel endogenous mechanism wherein EVs aggravate myocardial injury during the onset of AMI via endothelial cell-secreted miR-503 shuttling.
Responsed Disease Injury of heart ICD-11: NB31
 Disease Info 
In-vivo Model To generate an AMI mouse model, mice were anesthetised by intraperitoneal injection of sterile pentobarbital sodium at 50 mg/kg body weight.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
NB31: Injury of heart 6 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name MyoCell Phase 2/3 [2]
Synonyms
MyoCell (TN)
    Click to Show/Hide
External Link
TTD: D0O7CO
 Compound Name Diannexin Phase 2 [3]
External Link
TTD: D07FQL
 Compound Name CMX-2043 Phase 2 [4]
External Link
CID: 49802864
TTD: D01TBJ
DrugBank: DB12795
 Compound Name ED1 Investigative [5]
Synonyms
ethylenediamine scaffold, 10; BDBM31426; 3-{2'-[{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}(2-{(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino}ethyl)sulfamoyl]biphenyl-3-yl}propanoic acid
    Click to Show/Hide
External Link
CID: 25181318
TTD: D0G1SN
 Compound Name ED45 Investigative [5]
External Link
TTD: D01NJE
 Compound Name DD7 Investigative [5]
External Link
TTD: D00QBV
References
Ref 1 Extracellular vesicle-packaged mitochondrial disturbing miRNA exacerbates cardiac injury during acute myocardial infarction. Clin Transl Med. 2022 Apr;12(4):e779. doi: 10.1002/ctm2.779.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 ClinicalTrials.gov (NCT00615966) Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients. U.S. National Institutes of Health.
Ref 4 ClinicalTrials.gov (NCT02103959) Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography. U.S. National Institutes of Health.
Ref 5 Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.